Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (3): 254-259.doi: 10.3969/j.issn.1000-6621.2019.03.003
• Original Articles • Previous Articles Next Articles
Juan-wen LIAN,Jia-ling XU,Tao HUA,Jie DING,Yu FAN()
Received:
2018-10-18
Online:
2019-03-10
Published:
2019-03-15
Contact:
Yu FAN
E-mail:LF85325060@163.com
Juan-wen LIAN,Jia-ling XU,Tao HUA,Jie DING,Yu FAN. Clinical characteristics and related factors of patients with secondary tuberculosis after malignant tumors[J]. Chinese Journal of Antituberculosis, 2019, 41(3): 254-259. doi: 10.3969/j.issn.1000-6621.2019.03.003
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.03.003
临床指标 | 观察组 (163例) | 单纯结核病组 (100例) | 统计值 | P值 |
---|---|---|---|---|
平均年龄(岁, | 62.50±9.02 | 53.67±7.64 | t=2.65 | 0.014 |
血红蛋白(g/L, | 114.50±7.99 | 115.89±9.51 | t=0.38 | 0.709 |
白蛋白(g/L, | 31.69±4.21 | 33.54±3.75 | t=1.32 | 0.203 |
性别[例(构成比,%)] | χ2=1.50 | 0.219 | ||
男 | 105(64.42) | 58(58.00) | ||
女 | 58(35.58) | 42(42.00) | ||
吸烟[例(构成比,%)] | χ2=1.52 | 0.207 | ||
是 | 99(60.74) | 53(53.00) | ||
否 | 64(39.26) | 47(47.00) | ||
发热[例(构成比,%)] | χ2=4.20 | 0.040 | ||
有 | 104(63.80) | 51(53.00) | ||
无 | 59(36.20) | 48(48.00) | ||
乏力[例(构成比,%)] | χ2=5.03 | 0.025 | ||
有 | 68(41.72) | 28(28.00) | ||
无 | 95(58.28) | 72(72.00) | ||
体质量减轻[例(构成比,%)] | χ2=16.18 | 0.000 | ||
有 | 78(47.85) | 23(23.00) | ||
无 | 85(52.15) | 77(77.00) |
临床指标 | 观察组 (163例) | 单纯恶性肿瘤组 (100例) | χ2值 | P值 |
---|---|---|---|---|
年龄(岁) | 4.14 | 0.042 | ||
≥60 | 119(73.01) | 61(61.00) | ||
<60 | 44(26.99) | 39(39.00) | ||
吸烟 | 0.64 | 0.425 | ||
是 | 101(61.96) | 57(57.00) | ||
否 | 62(38.04) | 43(43.00) | ||
性别 | 0.94 | 0.334 | ||
男 | 99(60.73) | 61(61.00) | ||
女 | 64(39.27) | 39(39.00) | ||
既往结核病史 | 4.27 | 0.031 | ||
有 | 37(22.70) | 12(12.00) | ||
无 | 126(77.30) | 88(88.00) | ||
TNM分期 | 4.30 | 0.038 | ||
Ⅰ~Ⅱ | 35(21.47) | 33(33.00) | ||
Ⅲ~Ⅳ | 128(78.53) | 67(67.00) | ||
ECOG评分 | 1.88 | 0.170 | ||
0~1 | 111(68.10) | 76(76.00) | ||
2分以上 | 52(31.90) | 24(24.00) | ||
肿瘤治疗 | 5.40 | 0.020 | ||
是 | 105(64.42) | 78(78.00) | ||
否 | 58(35.58) | 22(22.00) | ||
手术治疗 | 3.29 | 0.070 | ||
是 | 49(30.06) | 41(41.00) | ||
否 | 114(69.94) | 59(59.00) | ||
放疗 | 0.03 | 0.879 | ||
是 | 34(20.86) | 21(21.00) | ||
否 | 129(79.14) | 79(79.00) | ||
化疗 | 4.23 | 0.040 | ||
是 | 95(58.28) | 49(49.00) | ||
否 | 68(41.72) | 51(51.00) |
[1] | 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508. |
[2] |
Cai Y, Xue M, Chen W , et al. Expenditure of hospital care on cancer in China, from 2011 to 2015. Chin J Cancer Res, 2017,29(3):253-262.
doi: 10.21147/j.issn.1000-9604.2017.03.11 URL pmid: 28729776 |
[3] |
Chen L, Files DB . Molecular mechanisms of T cells co-stimulation and co-inhibition. Nat Rev Immunol, 2013,13(4):227-242.
doi: 10.1038/nri3405 URL pmid: 23470321 |
[4] | 马玙 . 肺结核与肺癌. 中国实用内科杂志, 2015,35(8):675-678. |
[5] |
张蕾, 赵微微, 王春丽 . 肺结核并发肺癌患者临床特征的研究现状. 中国防痨杂志, 2017,39(4):420-423.
doi: 10.3969/j.issn.1000-6621.2017.04.021 URL |
[6] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09. |
[7] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09. |
[8] | 高孟秋 . 《WS 288—2017 肺结核诊断》新标准中关于临床诊断患者判定的解析. 中国防痨杂志, 2018,40(3):243-246. |
[9] |
刘二勇, 周林, 王黎霞 . 《WS 196—2017 结核病分类》标准全面解读. 中国防痨杂志, 2018,40(3):234-238.
doi: 10.3969/j.issn.1000-6621.2018.03.003 URL |
[10] |
Pan WY, Lo CH, Chen CC , et al. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther, 2012,20(5):927-937.
doi: 10.1038/mt.2012.10 URL pmid: 22334018 |
[11] | 林薇 . 恶性肿瘤患者合并结核感染的风险性研究. 重庆:第三军医大学, 2015. |
[12] |
吕子征, 王伟, 刘京铭 , 等. 初治结核病患者自噬相关基因表达水平的研究. 中国防痨杂志, 2017,39(1):82-85.
doi: 10.3969/j.issn.1000-6621.2017.01.018 URL |
[13] |
Dheda K, Schwander SK, Zhu B , et al. The immunology of tuberculosis: from bench to bedside. Respirology, 2010,15(3):433-450.
doi: 10.1111/j.1440-1843.2010.01739.x URL pmid: 20415982 |
[14] |
Simonsen DF, Farkas DK, Søgaard M , et al. Tuberculosis and risk of cancer: a Danish nationwide cohort study. Int J Tuberc Lung Dis, 2014,18(10):1211-1219.
doi: 10.5588/ijtld.14.0161 URL pmid: 25216835 |
[15] |
Nalbandian A, Yan BS, Pichugin A , et al. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene, 2009,28(17):1928-1938.
doi: 10.1038/onc.2009.32 URL pmid: 19330024 |
[16] |
柴梅, 史清明, 顾康生 . 合肥地区恶性肿瘤患者中肺结核的患病率调查. 中华疾病控制杂志, 2015,19(6):564-566.
doi: 10.16462/j.cnki.zhjbkz.2015.06.007 URL |
[17] |
郭佑民 . 正确发挥医学影像学技术在肺结核诊断中的作用. 中国防痨杂志, 2017,39(6):549-551.
doi: 10.3969/j.issn.1000-6621.2017.06.001 URL |
[18] |
Yong SJ, Lee M, Lee WY , et al. PS01.18: the characteristics of active pulmonary tuberculosis in lung cancer patients: topic: pulmonology. J Thorac Oncol, 2016,11(11S):S279-S280.
doi: 10.1016/j.jtho.2016.09.053 URL pmid: 27969484 |
[19] |
张君国, 张雯, 王买红 , 等. 肺癌合并肺结核的临床特征分析. 中华肺部疾病杂志(电子版), 2018,11(3):271-274.
doi: 10.3877/cma.j.issn.1674-6902.2018.03.003 URL |
[20] | 姜世闻 . 《结核病分类》和《肺结核诊断》新标准对结核病控制工作的影响. 中国防痨杂志, 2018,40(3):229-230. |
[21] | 廉娟雯, 党丽云, 许家玲 , 等. 结核感染T细胞斑点试验在恶性肿瘤并发结核病患者中的应用价值. 中国防痨杂志, 2018,40(4):353-357. |
[22] |
Simonsen DF, Farkas DK, Horsburgh CR , et al. Increased risk of active tuberculosis after cancer diagnosis. J Infect, 2017,74(6):590-598.
doi: 10.1016/j.jinf.2017.03.012 URL pmid: 28366685 |
[23] |
Fang WL, Hung YP, Liu CJ , et al. Incidence of and risk factors for tuberculosis (TB) in gastric cancer patients in an area endemic for TB: a nationwide population-based matched cohort study. Medicine (Baltimore), 2015,94(47):e2163.
doi: 10.1097/01.md.0000496597.44876.e4 URL |
[24] |
Kim HR, Hwang SS, Ro YK , et al. Solid-organ malignancy as a risk factor for tuberculosis. Respirology, 2008,13(3):413-419.
doi: 10.1111/j.1440-1843.2008.01282.x URL pmid: 18399865 |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||